Business Wire

KS-TREVIPAY

16.1.2024 13:01:34 CET | Business Wire | Press release

Share
TreviPay and Mastercard Partner to Launch B2B Net Terms Financing Capabilities for Any Supplier Accepting Credit Cards

TreviPay, the most-trusted B2B payments and invoicing network, today announced the launch of its Universal Acceptance solution to expand supplier access to and faster implementation of TreviPay’s payments and invoicing technology, in partnership with Mastercard. Suppliers who accept Mastercard will be able to extend net terms, or trade credit financing, and SKU-level invoicing to business buyers through TreviPay’s Universal Acceptance solution using Mastercard’s commercial card payment capabilities.

Research1 commissioned by TreviPay unveiled the top three pain points of global business buyers are inefficient processes, incorrect invoicing and slow onboarding. The same research ranked trade credit as a leading payment option preferred by business buyers. With minimal integration required, TreviPay’s Universal Acceptance solution enables suppliers who are already accepting credit cards to quickly and easily offer net-terms financing to their qualified buyers, while taking on no credit risk. TreviPay automates the buyer onboarding, financing and accounts receivable process to drive payment efficiencies and streamline time-consuming back-office operations.

“TreviPay’s technology was developed to eliminate the complexities of B2B purchasing and create a consumer-like purchasing experience while still catering to the needs and requirements of business buyers,” said Brandon Spear, CEO of TreviPay. “Joining forces with Mastercard to launch the Universal Acceptance solution marks an industry milestone in expanding access to TreviPay’s solution, a leading B2B payment method of corporate sellers and their buyers globally. Together we are revolutionizing how businesses can transact by bringing flexible extended payment terms to more buyers.”

With TreviPay leveraging Mastercard’s global acceptance network and commercial card payment capabilities, suppliers are able to provide approved buyers with a net-terms card for purchasing, offering the checkout convenience of a credit card, as well as the auditability and purchase controls of trade credit. The TreviPay platform then automatically delivers invoices directly to the merchant’s buyer, eliminating the costs associated with chasing outstanding or late payments, assuming all risk associated with collection and guaranteeing settlement to the merchant upfront.

“Mastercard is committed to building industry partnerships that help suppliers better meet the purchasing needs of their B2B customers and drive loyalty,” said Rebecca Meeker, Senior Vice President, Global Partnerships and Segments, Mastercard. “With a shared vision to bring consumer-grade convenience to B2B transactions, we are proud to deepen our collaboration with TreviPay as they facilitate variable financing options, seamless invoice reconciliation and faster settlement when using cards on our network.”

With the addition of the Universal Acceptance solution, the TreviPay platform can now be implemented for suppliers in two ways: the original API integration of the platform directly into the seller’s point of acceptance, or without API integration, by instead leveraging Mastercard’s global acceptance network.

This announcement comes shortly after TreviPay’s launch of Financial Partner Gateway, a new suite of APIs for financial institutions looking to expand commercial offerings. The Universal Acceptance solution complements this offering as another way TreviPay is expanding its global footprint and optimizing the payment experience for suppliers.

Read more about TreviPay’s Universal Acceptance solution.

1 The study was conducted by Murphy Research on behalf of TreviPay from May 17 to June 2, 2023. The results are based on a comprehensive review of 300 global B2B buyers.

About TreviPay

At TreviPay, we believe loyalty begins at the payment. By understanding the diverse and unique requirements of B2B sellers, TreviPay’s global B2B payments and invoicing network enables enterprises to provide payments choice and convenience, open new markets and automate accounts receivables. With more than four decades of experience, TreviPay serves leaders looking to build loyalty while driving efficiency and embracing new digital channels, especially in industries with large distribution networks such as manufacturing, retail, and transportation. For more information, visit trevipay.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116535144/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye